News >

Expert Calls for Smarter Clinical Trials in Pancreatic Neoplasms

Angelica Welch
Published: Friday, May 18, 2018

Paul E. Oberstein, MD

Paul E. Oberstein, MD
Although new agents have demonstrated benefit in the treatment of patients with advanced pancreatic neoplasms, outcomes remain poor, said Paul E. Oberstein, MD. In the United States, about 50% of patients with metastatic pancreatic adenocarcinoma will die within 2 months of diagnosis. Additionally, 50% of elderly patients never receive any therapy. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication